Literature DB >> 30228706

Surgical Management for Prostate Cancer.

Eric H Kim1, Arnold D Bullock2.   

Abstract

For prostate cancer, radical prostatectomy remains the gold standard for surgical management. Given the side effects associated with surgery, patients at low risk of prostate cancer-specific mortality should consider active surveillance under the guidance of a urologist to safely delay intervention. For patients with an intermediate risk of cancer-specific mortality and otherwise healthy life expectancy, radical prostatectomy has been demonstrated to improve survival. Finally, even for select patients with advanced prostate cancer-metastatic disease to the lymph nodes or distant sites-radical prostatectomy may provide a survival benefit.

Entities:  

Mesh:

Year:  2018        PMID: 30228706      PMCID: PMC6139865     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


  21 in total

Review 1.  Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy.

Authors:  Ashutosh Tewari; Prasanna Sooriakumaran; Daniel A Bloch; Usha Seshadri-Kreaden; April E Hebert; Peter Wiklund
Journal:  Eur Urol       Date:  2012-02-24       Impact factor: 20.096

2.  Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?

Authors:  Pia Bader; Fiona C Burkhard; Regula Markwalder; Urs E Studer
Journal:  J Urol       Date:  2003-03       Impact factor: 7.450

Review 3.  Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies.

Authors:  Vincenzo Ficarra; Giacomo Novara; Walter Artibani; Andrea Cestari; Antonio Galfano; Markus Graefen; Giorgio Guazzoni; Bertrand Guillonneau; Mani Menon; Francesco Montorsi; Vipul Patel; Jens Rassweiler; Hendrik Van Poppel
Journal:  Eur Urol       Date:  2009-01-25       Impact factor: 20.096

4.  Follow-up of Prostatectomy versus Observation for Early Prostate Cancer.

Authors:  Timothy J Wilt; Karen M Jones; Michael J Barry; Gerald L Andriole; Daniel Culkin; Thomas Wheeler; William J Aronson; Michael K Brawer
Journal:  N Engl J Med       Date:  2017-07-13       Impact factor: 91.245

Review 5.  Focal therapy for prostate cancer: possibilities and limitations.

Authors:  Scott Eggener; Georg Salomon; Peter T Scardino; Jean De la Rosette; Thomas J Polascik; Simon Brewster
Journal:  Eur Urol       Date:  2010-03-26       Impact factor: 20.096

Review 6.  Pathological Findings in Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion-guided Biopsy: Relation to Prostate Cancer Focal Therapy.

Authors:  Jennifer Gordetsky; Soroush Rais-Bahrami; Jonathan I Epstein
Journal:  Urology       Date:  2017-02-24       Impact factor: 2.649

Review 7.  Active surveillance for prostate cancer: a systematic review of the literature.

Authors:  Marc A Dall'Era; Peter C Albertsen; Christopher Bangma; Peter R Carroll; H Ballentine Carter; Matthew R Cooperberg; Stephen J Freedland; Laurence H Klotz; Christopher Parker; Mark S Soloway
Journal:  Eur Urol       Date:  2012-06-07       Impact factor: 20.096

8.  Comparative effectiveness of minimally invasive vs open radical prostatectomy.

Authors:  Jim C Hu; Xiangmei Gu; Stuart R Lipsitz; Michael J Barry; Anthony V D'Amico; Aaron C Weinberg; Nancy L Keating
Journal:  JAMA       Date:  2009-10-14       Impact factor: 56.272

9.  Radical prostatectomy or watchful waiting in early prostate cancer.

Authors:  Anna Bill-Axelson; Lars Holmberg; Hans Garmo; Jennifer R Rider; Kimmo Taari; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Anders Spångberg; Ove Andrén; Juni Palmgren; Gunnar Steineck; Hans-Olov Adami; Jan-Erik Johansson
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

10.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.

Authors:  Laurence Klotz; Liying Zhang; Adam Lam; Robert Nam; Alexandre Mamedov; Andrew Loblaw
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.